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http://dx.doi.org/10.1016/j.ajic.2014.12.021Two rapid methods of Clostridium difﬁcile infection (CDI) diagnosis were compared between June 2012
and March 2013: a GeneXpert (Cepheid, Sunnyvale, Calif) polymerase chain reaction (PCR) test and an
enzyme immunoassay (EIA). The inﬂuence of these methods on the detection of hospital-acquired CDI
and identiﬁcation of CDI outbreaks was evaluated. We tested 1,592 stool samples for C difﬁcile. The
GeneXpert PCR test identiﬁed 211 positive samples (68 determined to be hospital-acquired infection),
whereas EIA identiﬁed 105 positive samples (36 determined to be hospital-acquired infection). The
GeneXpert PCR method in contrast to the EIA method increased the detection rates of nosocomial CDI
cases and contributed to the declaration of CDI outbreaks.
Copyright  2015 by the Association for Professionals in Infection Control and Epidemiology, Inc.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license (http://
creativecommons.org/licenses/by-nc-sa/4.0/).Several laboratorymethods are available to diagnose Clostridium
difﬁcile infection (CDI), including enzyme immunoassay (EIA)-
based tests, stool cultures, and nucleic acid ampliﬁcation tests. EIA
and polymerase chain reaction (PCR) tests are fast methods for CDI
diagnosis, but they vary in their sensitivities and speciﬁcities.1 The
use of these methods can affect the correct diagnosis of CDI, patient
management, and deployment of infection control protocols.
Although there has been a near consensus on the superiority of PCR
methods detecting C difﬁcile in terms of sensitivity and turnaround
time,2 many laboratories still use EIA assay mostly due to cost
issues.
In this report, we compare the EIA and the GeneXpert PCR
(Cepheid, Sunnyvale, Calif) test methods and the inﬂuence of
using these diagnostic tools on CDI rates in a Canadian acute-care
facility.a, MD, PhD, Advanced Med-
Sudbury, ON P3E 5J1 Canada.
itoma).
ofessionals in Infection Control and
nses/by-nc-sa/4.0/).MATERIALS AND METHODS
Study design and patient population
All work performed in this study was approved by our Institu-
tional Research Ethics Board. This was an observational study, with
a population composed of all patients tested for C difﬁcile by the
Microbiology Laboratory at Health Sciences North, Sudbury,
Ontario, Canada, between June 2012 and March 2013. During the
study period, 978 patients were tested, producing total 1,592
samples tested for C difﬁcile. Health Sciences North is a 500-bed
acute-care teaching health care center, where provincial best
practice infection prevention and control measures are followed.
The deﬁnition described by the Ontario Provincial Infectious Dis-
eases Advisory Committee was followed to identify hospital-
acquired CDI cases and the declaration of the 2 C difﬁcile outbreaks.3Testing C difﬁcile samples in the clinical laboratory using the EIA
method and the GeneXpert platform
Only nonformed stools were accepted for C difﬁcile testing. The
same stool sample was used to perform the EIA and GeneXpert PCREpidemiology, Inc. Published by Elsevier Inc. This is an open access article under the
AB
Fig 1. (A) The moving average frequency of Clostridium difﬁcile positive samples tested at the Health Services North Microbiology Department between June 2012 and March 2013
using GeneXpert polymerase chain (Cepheid, Sunnyvale, Calif) reaction and enzyme immunoassay (EIA) methods. (B) The total number of positive and negative tests performed
using EIA and GeneXpert PCR testing methodologies. A positive rate of 13% was detected when GeneXpert PCR was used versus 6% when EIA was used.
Y.M. Murad et al. / American Journal of Infection Control 43 (2015) 383-6384tests. To perform the EIA assay test we used the ImmunoCard
Toxins A and B (Meridian, Memphis, Tenn) and for the PCR assay,
the GeneXpert C difﬁcile Epi (Cepheid) test was used. The manu-
facturer’s instructions were followed in both cases. Results were
reported as either C difﬁcile toxin detected or C difﬁcile toxin not
detected. If the C difﬁcile toxin was detected in a patient sample by
either method, or by both, the sample was reported as positive.
RESULTS
Study design and inﬂuence of GeneXpert PCR test on CDI rates
The EIA and GeneXpert PCR tests were run concurrently in our
Microbiology Laboratory. Collected data were used to study the
effect of switching the testing methodology on the rates of CDI.
Patients tested were evenly split between men and women.
More than 80% of the tested samples were from patients older than
age 50 years, and about 75% of the tested patients were inpatients.
Higher rates of patients with CDI were detected using the
GeneXpert platform compared with the EIA method. Unweighted
moving average analysis of weekly positive frequency tests with a
2-week periodicity showed this to be a consistent trend (Fig 1). The
GeneXpert PCR test detected twice as many CDI-positive cases as
the EIA test (n ¼ 211 vs n ¼ 105, respectively) (Fig 1). When
compared with the hospital historical ﬁgures, this result indicates a
sharp increase in the number of patients diagnosed with CDI.
From the 211 samples that tested positive for C difﬁcile using
the GeneXpert PCR test, 68 samples came from patients who were
determined to have hospital-acquired infection by our Infection
Prevention and Control Department. Thirty-two hospital-acquired
CDI cases tested negative using EIA and 36 were positive
using EIA.
Inﬂuence of the GeneXpert PCR test on the identiﬁcation of
C difﬁcile outbreaks
Two C difﬁcile outbreaks were declared at Health Sciences North
during the period between September and December 2012 in 2
wards; an oncology ward (ward A) and a respiratory medical ward
(ward B). During the outbreak period, a total of 33 inpatients in the
2 affected wards tested positive for C difﬁcile using either the EIAtest or GeneXpert PCR test. Out of the total number, 22 patients
were determined to have acquired CDI in these 2 wards (15 inward
A and 7 in ward B). Out of the 22 patients with hospital-acquired
CDI, 20 tested positive for C difﬁcile by using the GeneXpert PCR
testing platform (2 samples were not available for testing using the
GeneXpert PCR test). Only 12 out of the 22 CDI-positive patients
tested positive using the EIA method, 9 were negative, and 1
sample was not tested using EIA (Fig 2).
In both outbreaks, the number of nosocomial CDI cases
initially identiﬁed by the EIA method was below the threshold
determined by the Ontario Provincial Infectious Diseases Advisory
Committee to declare a C difﬁcile outbreak. These results indicate
that the identiﬁcation of the outbreaks would have been delayed
in the 2 affected wards if only an EIA test was used at the time
(Figs 2 and 3).DISCUSSION
The introduction of a more sensitive, PCR-based method for
testing C difﬁcile had a profound inﬂuence on the detection and the
rate of CDI at Health Sciences North. Using GeneXpert PCR for the
testing of CDI contributed not only to the detection of hospital-
acquired cases of CDI, but also to the detection of outbreaks. In
this report, we show that the GeneXpert PCR test assisted in
deﬁning the duration of 2 CDI outbreaks in our facility in 2012.
As shown in Figures 2 and 3, we identiﬁed hypothetical sce-
narios where only EIA results were used to identify outbreaks. The
scenarios show a delay in declaring the outbreaks, and an early end
of the outbreaks. A previous study has shown that a “pseudo-
outbreak” was declared in a hospital due to a faulty detection kit,
leading to many false-positive CDI cases.4 These misidentiﬁed
cases can drain hospital resources and adversely affect patients.
However, our study underlines that using a less-sensitive method
to diagnose CDI may increase the chances of spreading C difﬁcile
withinwards. We also recognize that the high sensitivity of the PCR
test has the potential to overdiagnose cases of CDI. A large study in
the United Kingdom found that the PCR test used alone may
identify colonized patients as having CDI, suggesting the use of a
cytotoxin assay in the algorithm to correctly identify patients with
hospital-acquired CDI.5
Fig 2. Timeline distribution of Clostridium difﬁcile infection (CDI) cases identiﬁed during the outbreak period in ward A (September 12, 2012-December 19, 2012). (A) The actual total
hospital acquired CDI cases detected and outbreak timeline. (B) A hypothetical timeline for hospital-acquired CDI cases and outbreak if only enzyme immunoassay method was used.
Fig 3. Timeline distribution of Clostridium difﬁcile infection cases identiﬁed during the outbreak period inward B (October 25, 2012-December 11, 2012). (A) The actual total hospital-
acquired CDI cases detected and outbreak timeline. (B) A hypothetical timeline for hospital-acquired CDI cases and outbreak if only the enzyme immunoassay method was used.
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Y.M. Murad et al. / American Journal of Infection Control 43 (2015) 383-6386CONCLUSIONS
The factors contributing to CDI rates in a hospital are complex.
The method used for the detection of C difﬁcile is a major factor in
the detection of CDI, and in the declaration and end of outbreaks.
Improved diagnostic methods and a robust antibiotic stewardship
program,6 in addition to infection control policies and practices,
environmental cleaning,7 improving hand hygiene practices,8
hospital design,9 and better identiﬁcation of asymptomatic car-
riers10 should all result in better control of CDI.
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